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In this Research Topic on Pathogens, Pathobionts and Autoimmunity, we explore how viruses,
bacteria, and commensals can contribute to autoimmunity. The articles presented are either reviews
of the literature or original data on mechanisms by which pathogens and pathobionts may trigger
autoimmune disease. Several articles are devoted to viruses that have previously been associated
with autoimmunity. In particular, Epstein Barr virus (EBV) has frequently been implicated in a
number of autoimmune diseases and several mechanisms have been identiﬁed. These are discussed
in the two reviews by Houen et al. (Houen and Trier; Houen et al.) and by Jog and James and in
original research articles by Munroe et al. and Farina et al. In their review entitled “Epstein-Barr
Virus and Systemic Autoimmune Diseases”, Houen and Trier offer possible mechanistic
explanations for how EBV can trigger diverse disease manifestations in different individuals.
They suggest that this may be inﬂuenced by the predominant cell types that are infected with EBV in
different individuals, such as memory B cells or epithelial cells. In their review on “Epstein-Barr
virus and Multiple Sclerosis”, Houen et al. focus on recent studies suggesting that EBV-transformed
B cells that enter the central nervous system are direct participants in Multiple Sclerosis (MS)
pathogenesis and that monoclonal antibody therapy targeting CD20-positive memory B cells is an
effective treatment for patients with relapsing remitting MS and with primary progressive MS.
In their review on “Epstein Barr Virus and Autoimmune Responses in Systemic Lupus
Erythematosus”, Jog and James discuss several mechanisms by which EBV can contribute to
systemic lupus erythematosus (SLE), including molecular mimicry, dysregulated anti-EBV T cell
responses, single nucleotide polymorphisms in the CD40, IL10, and CTLA4 genes associated with
SLE that also facilitate EBV re-activation, and recently identiﬁed SLE risk alleles known to bind
strongly to the EBV EBNA-2 protein (1–7). In addition, they describe how EBV viral proteins, such
as viral IL-10 (vIL-10) and latent membrane protein 1 (LMP-1), which are homologues of human
proteins that alter immune responses, can potentially lead to SLE and how noncoding EBV viral
RNAs can lead to activation of IFN-a, a pro-inﬂammatory cytokine associated with SLE (8, 9).
Finally, they summarize several animal models including humanized mice, that are currently being
used to study the role of EBV in autoimmunity.
In a primary article in this Research Topic, Munroe et al. examine the role of EBV LMP1 in SLE.
LMP1 is a functional mimic of CD40 that can activate B cells. Mice transgenic for a mCD40-LMP1
hybrid molecule have splenomegaly, lymphadenopathy, an expanded population of immature/
activated B-lymphocytes and slightly elevated levels of autoantibodies (10). It has previously been
shown that mice injected with EBV nuclear antigen 1 (EBNA-1) develop antibodies that cross-react
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microbes within the Lachnospiraceae family and an increase in proinﬂammatory microbes such as Ruminococcus gnavus (that has been
reassigned to the genus Blautia) are observed in a subset of patients
with IBD, and have been linked to lupus nephritis pathogenesis (15).
They also review studies demonstrating how molecular mimicry
may be the mechanism by which the gut microbiota is linked to SLE.
They describe how autoantibodies and autoreactive T cells speciﬁc
for Ro60 may arise due to cross-reactivity with a Ro60 ortholog
protein produced by gut commensals and how autoantibodies to
lipoglycans in Ruminococcus gnavus are linked to the generation of
anti-dsDNA autoantibodies (15).
In a primary research report, Bagavant et al. (https://pubmed.
ncbi.nlm.nih.gov/34122404/), investigate a link between
Enterococcus gallinarum, a gram-positive bacteria found in the
gut, and SLE. They observe that SLE patients with antibodies to
Ribosomal P (three phosphorylated proteins on the 60s subunit
of ribosomes) have higher titers of IgG antibodies to E.
gallinarum than healthy individuals. They also observe higher
titers of serum IgG antibodies to E. gallinarum in SLE patients
with antibodies to dsDNA, Sm, and RNA. They suggest that E.
gallinarum may inﬂuence the subset of autoantigens targeted in
lupus patients and infer that molecular mimicry may play a role.
Disruption of the intestinal barrier plays a role in inﬂammatory
autoimmune responses as it allows bacteria to translocate into sites
outside the gut that they don’t normally inhabit. In one of two
primary research reports in this Research Topic by Zhang et al.
they demonstrate that intestinal barrier disruption and
translocation of bacteria into the liver can trigger autoimmune
hepatitis (AIH). They also show that liver macrophages activated
by receptor interacting protein 3 (RIP3), a regulator of necrosis/
necroptosis, can contribute to the liver damage observed in AIH by
their secretion of pro-inﬂammatory cytokines. Furthermore, they
demonstrate that antibiotic treatment can inhibit RIP3
accumulation and activation of liver macrophages, thereby
ameliorating disease. This supports their hypothesis that
microbiota play a role in AIH and suggests that RIP3 can be a
potential therapeutic target in this autoimmune disease. In their
second report in this Research Topic, Zhang et al. examine the role
of the commensal gut bacterium Biﬁdobacterium animalis (B420)
that is found in probiotics, in the treatment of experimental
autoimmune hepatitis in mice (EAH). They observe pathobiont
dysbiosis in EAH mice with a reduction in fecal anerobes and an
expansion in potentially pathogenic bacteria such as Bacteroides
and Ruminococcus. They also observe that certain short chain fatty
acids (SCFAs) such as butyric acids are decreased in AIH patients
and EAH mice and that RIP3 is increased. They now demonstrate
that B420 treatment can improve the intestinal barrier, increase the
level of butyric acids and lower the levels of RIP3, all of which have
protective effects. These results reveal that B420 can ameliorate liver
damage in EAH mice and suggest that modulation of the gut
microbiota with probiotics has potential in the treatment of AIH.
Finally, an original and a review article in this Research Topic
examines the role of the gut microbiome in ankylosing
spondyloarthropathies. There is much overlap between
spondyloarthropathies and gut inﬂammation, and many patients
with a spondyloarthropathy also have gut inﬂammation, while some
patients with IBD have spondyloarthritis (SpA) (16). Therefore, the

with the ribonucleoprotein, Sm B due to molecular mimicry of a
peptide in EBNA-1 that is highly homologous to a peptide in Sm
B (11, 12). In the current study, Munroe et al. demonstrate that
lymphocytes from mCD40-LMP1 mice injected with EBNA-1
develop signiﬁcantly greater cellular and humoral immune
responses to EBNA-1 and to Sm B than lymphocytes from
wild type mice and have elevated ANAs and anti-dsDNA
antibodies due to epitope spreading to DNA protein
complexes. This suggests that E BV can a ccelerate
autoimmunity in SLE by providing a combination of signals;
one that leads to immune dysregulation and another that elicits a
cross-reactive autoimmune response.
EBV is also associated with systemic sclerosis (SSc, scleroderma)
pathogenesis. In their primary research article, Farina et al. (https://
www.ncbi.nlm.nih.gov/pmc/articles/PMC8089375/) demonstrate
that EBV can indirectly infect endothelial cells (ECs) using
monocytes bound to EBV as a shuttle. They previously
demonstrated that monocytes from SSc patients carry EBV and
that these monocytes can adhere to the endothelium (13). In the
current report, they show that once in ECs, EBV can activate TLR9
and INF-a inducible genes and trigger an innate, pro-inﬂammatory
response that can lead to vascular damage, seen in the early stages of
SSc. Understanding the role of EBV in vascular injury in SSc, may
lead to therapeutic strategies aimed at preventing viral infection.
In addition to EBV, other viruses have also been associated with
autoimmunity. In an extensive review in this Research Topic,
Mustelin and Ukadike discuss various mechanisms by which
retroviruses and retrotransposons in our genome can contribute
to rheumatological autoimmune diseases. A large part of the human
genome consists of retroviral sequences or retrotransposons that
have been reverse transcribed and integrated into our genome (14).
Mustelin and Ukadike cite studies demonstrating that the
expression of certain human endogenous retroviral RNAs
(HERV-K and HERV-E) and retroviral proteins are increased in
SLE and RA patients. These retroviral proteins are believed to elicit
autoantibodies. Mustelin and Ukadike also describe studies
demonstrating how elevated levels of retrotransposon RNA
transcripts such as long interspersed nuclear elements (L1) in SLE
patients, can bind the ribonucleoproteins Ro60 and La as well as the
viral ORF1p protein to form complexes which can serve as target
autoantigens in SLE. In addition, they review how these endogenous
viruses can interact with RNA and DNA sensors to elicit the
production of IFN-a and thereby promote SLE pathogenesis.
Therapeutic strategies that target IFN-a, including the recently
FDA-approved anifrolimumab, or that inhibit reverse
transcriptase or DNA and RNA sensors, are also discussed.
Many bacteria have also been linked to autoimmune diseases
especially those that populate the gut microbiome. Alterations in the
types and concentrations of bacteria that normally inhabit the gut
microbiome and changes in the environment in the gut have been
observed to contribute to autoimmunity. In their review article, Wu
et al. discuss how microbial dysbiosis in the gut and disturbances in
several pathways that affect the interaction of gut microbes with the
host, may play a role in disease pathogenesis in SLE, inﬂammatory
bowel disease (IBD), rheumatoid arthritis (RA), MS, and type I
diabetes (https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC7786055/). They note how a reduction in anti-inﬂammatory
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pathogenesis of these inﬂammatory diseases may be intertwined.
Using metabolomics and metagenomics, Berlinberg et al. address the
inﬂuence of gut dysbiosis on tryptophan metabolism and the
relevance for SpA pathogenesis. They observe that there is an
expansion in certain tryptophan metabolites such as indole-3acetate (IAA) and indole-3-acetaldehyde (I3Ald) in individuals
with SpA, irrespective of whether they also have associated
Crohn’s disease (CD), suggesting that the presence of these
metabolites is speciﬁc to SpA. They also observe that the gut
communities of SpA patients commonly have increases in the
representation of microbial genes involved in tryptophan
metabolism, whereas in healthy individuals there is instead an
elevation in genes involved in tryptophan synthesis. The authors
suggest that the inﬂuence of the overall composition of the gut
microbiota communities may be more important in the alteration in
tryptophan metabolism leading to SpA than individual bacterial
species. This hypothesis is supported by Gill and Rosenbaum in their
review on “Putative pathobionts in HLA-B27-associated
spondyloarthropathy” https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC7848169/. They discuss various bacterial, fungal, and viral
pathobionts that are associated with HLA-B27 SpAs and
overlapping inﬂammatory diseases of the gut. They observe that
different microbes are associated with SpA and CD in different
individuals and that there doesn’t appear to be one consensus
microbe. They conclude that the microbiome community and the

interactions of the gut microbes with one another are what
determines whether HLA-B27 individuals will develop
inﬂammatory autoimmunity and that this is inﬂuenced by the
genetics of the individual and the environment.
In summary, this Research Topic elucidates many different
ways that viral pathogens and gut pathobionts can contribute to
autoimmunity. Each of these mechanisms may offer individual
pathways that can be targeted by therapeutic strategies.
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